Efinopegdutide Phase 2 trial (NCT05877547)
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 381
- actual
- Start
- 23 Jun 2023 (actual)
- Primary completion
- 29 Dec 2025 (actual)
- Sponsor
- Merck Sharp & Dohme LLC
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Efinopegdutide 4mg | Experimental | Drug: Efinopegdutide | Efinopegdutide administered by subcutaneous (SC) injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks and 4mg for 48 weeks. |
| Efinopegdutide 7mg | Experimental | Drug: Efinopegdutide | Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, and 7 mg for 44 weeks. |
| Efinopegdutide 10mg | Experimental | Drug: Efinopegdutide | Efinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for 40 weeks. |
| Placebo | Placebo comparator | Drug: Placebo | Placebo administered by SC injection once weekly for 52 weeks |
| Semaglutide 2.4 mg | Active comparator | Drug: Semaglutide | Semaglutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and 2.4 mg for 36 weeks. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52 | Week 52 |
| Percentage of Participants Who Experienced an Adverse Event (AE) | Up to 60 weeks |
| Percentage of Participants Discontinuing Study Medication Due to an AE | Up to 52 weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52 | Week 52 |
| Change from Baseline in Body Weight At Week 52 | Week 52 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic SteatohepatitisClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.